Test Price
2,800 AED✅ Home Collection Available
CD79A Gene Agammaglobulinemia Type 3, Autosomal Recessive Genetic Test | 2800 AED | Dubai Healthcare City
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) Accredited Processing. This test sequences the entire CD79A gene using next-generation sequencing (Illumina platform) to confirm autosomal recessive agammaglobulinemia type 3, a primary immunodeficiency characterized by absent B cells and severe hypogammaglobulinemia. The test includes VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM, telephonic post-test genetic counselling, and direct billing verification via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
The CD79A Gene Agammaglobulinemia Type 3 Test employs full-gene next-generation sequencing (NGS) to analyze the entire coding region and splice sites of the CD79A gene. This approach detects known and novel pathogenic variants with ≥99.9% sensitivity, enabling definitive diagnosis of autosomal recessive agammaglobulinemia type 3. Results must be interpreted alongside immunophenotyping and clinical history for comprehensive patient management.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Full‑Gene Next‑Generation Sequencing (Illumina‑based) | Single‑variant or limited‑region Sanger sequencing |
| Detection Rate | ≥99.9% sensitivity for known and novel CD79A variants | ~85% – only known hotspots; novel variants missed |
| Turnaround Time | 3‑4 Weeks | 5‑7 Days (limited scope) |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403):
Facing the possibility of a severe primary immunodeficiency in a child or family member is deeply unsettling. This NGS-based test provides definitive molecular evidence to eliminate diagnostic uncertainty, enabling timely initiation of immunoglobulin replacement therapy and precise genetic risk counselling for relatives. However, the genetic result must always be interpreted alongside immunophenotyping and clinical context—no single test stands alone.
Exclusion & Safety Criteria
🛡️ Important Safety Information
- This test is intended for individuals with clinical suspicion of agammaglobulinemia (recurrent severe infections, absent B‑cells). Family screening should only follow genetic counselling.
- If the patient develops high fever, severe respiratory distress, or signs of sepsis before the scheduled blood draw, proceed to the nearest Emergency Department immediately. Do not delay urgent care to obtain the sample.
- All clinical procedures, including specimen collection and result disclosure, comply with Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring patient safety and informed consent.
Patient FAQ & Clinical Guidance
1. What does the CD79A gene test detect?
This test identifies all pathogenic and likely pathogenic variants in the CD79A gene with 99.9% diagnostic sensitivity, confirming the molecular cause of autosomal recessive agammaglobulinemia type 3.
2. How is the sample collected and prepared?
We offer VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection between 8 AM and 11 PM. A single 2 mL EDTA whole blood sample or one drop of blood on an FTA card is sufficient; no fasting is required.
3. What is the turnaround time and how are results delivered?
Results are reported within 3 to 4 weeks through a secure, DHA‑compliant portal, and include a tele‑genetic counselling session to interpret findings and plan family screening.
UAE Regulatory & Data Privacy Adherence
📋 Compliance Framework
This test is performed under strict adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, anonymized, and processed exclusively within UAE jurisdiction. Patient consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring transparency and safety.
Clinical & Logistical Metadata
| Test Name | CD79A Gene Agammaglobulinemia Type 3, Autosomal Recessive Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | 2 mL EDTA whole blood or dried blood spot on FTA card; no fasting required |
| Methodology Used | Full-Gene Next-Generation Sequencing (Illumina-based) |
| ICD-10-CM Code | D80.0 |
| LOINC Code | 21659-9 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians